"10.1371_journal.pone.0102092","plos one","2014-07-18T00:00:00Z","Richie Khanna; Allan C Powe; Yi Lun; Rebecca Soska; Jessie Feng; Rohini Dhulipala; Michelle Frascella; Anadina Garcia; Lee J Pellegrino; Su Xu; Nastry Brignol; Matthew J Toth; Hung V Do; David J Lockhart; Brandon A Wustman; Kenneth J Valenzano","Amicus Therapeutics Inc., Cranbury, New Jersey, United States of America","Conceived and designed the experiments: RK ACP MJT HVD DJL BAW KJV. Performed the experiments: ACP YL RS JF RD MF AG LJP SX NB. Analyzed the data: RK ACP KJV. Contributed reagents/materials/analysis tools: RK ACP MJT. Wrote the paper: RK ACP BAW KJV.","Richie Khanna, Yi Lun, Rebecca Soska, Jessie Feng, Michelle Frascella, Anadina Garcia, Lee J. Pellegrino, Su Xu, Nastry Brignol, Hung V. Do, and Kenneth J. Valenzano are employed by Amicus Therapeutics and are shareholders in the company. Allan C. Powe, Jr., Rohini Dhulipala, Mathew J. Toth, David J. Lockhart, and Brandon A. Wustman are former employees of Amicus Therapeutics. Amicus Therapeutics funded the research and any publication fees. The recombinant human GAA (Lumizyme) used in this study is a product of Genzyme. There are no further patents, products in development, or marketed products to declare. This does not alter the authors' adherence to all of the PLOS ONE policies on sharing data and materials.","2014","07","Richie Khanna","RK",16,TRUE,7,10,3,4,TRUE,TRUE,FALSE,0,NA,FALSE
